secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0000899923-26-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics prelim Q4 revenue $207-209M, FY25 $822-824M; FY26 guidance $860-880M
--------------------------------------------------------------------------------

- Preliminary Q4 2025 total revenue $207-209M; full year 2025 revenue $822-824M.
- Full year 2025 test volumes ~1.5M (+1% YoY): hereditary cancer +7%, mental health +6%, prenatal -4%.
- FY 2026 revenue guidance $860-880M (midpoint +6% vs FY25 prelim midpoint).
- FY 2026 adjusted gross margin guidance 68-69%; adjusted EBITDA $37-49M (midpoint +43% vs prior FY25 guide).
- Formal Q4/FY 2025 earnings call scheduled for February 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000003/0000899923-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000003/mygn-20260112.htm
  HTML page:      https://secwatch.observer/filing/0000899923-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer